Plus therapeutics announces fda agreement to initiate respect-lm dose optimization trial for reyobiq™ in leptomeningeal metastases

Primary objective to determine optimal dosing schedule for a registrational trial trial builds on recommended phase 2 dose determined in completed phase 1 trial trial benefits from $17.6m award from the cancer prevention & research institute of texas houston, june 30, 2025 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (cns) cancers, today announces the initiation of the respect-lm dose optimization trial for reyobiqtm (rhenium re186 obisbemeda) for the treatment of leptomeningeal metastases (lm). the dose optimization trial follows encouraging results from the company's single-dose escalation trial and is designed to evaluate multiple-dose regimens of reyobiq administered at defined intervals via intraventricular catheter (ommaya reservoir).
PSTV Ratings Summary
PSTV Quant Ranking